ETI减少囊性纤维化患者修正性鼻窦手术
结果显示ETI后需手术患者比例从98%降至21%,年均手术频率从0.37次降至0.07次,差异均显著。
要点
- ETI治疗后需内镜鼻窦手术的患者比例由98%降至21%。
- 平均鼻窦手术次数由2.88次降至0.30次,差异有统计学意义。
- 年均手术频率由0.37次降至0.07次,提示鼻窦炎结局改善。
核心结论
- ETI与囊性纤维化患者内镜鼻窦手术频率和次数显著下降相关。
- 结果提示ETI可能改善囊性纤维化相关慢性鼻窦炎的结局。
研究设计与样本
- 回顾性病历审查,纳入2018年1月1日至2023年12月31日接受ETI治疗的6岁及以上囊性纤维化患者。
主要发现
- ETI启动时中位年龄13岁(IQR:10,23)。
- ETI前98%(n=55)需内镜鼻窦手术,ETI后降至21%(n=12)。
- 平均手术次数从2.88±1.68降至0.30±0.63(均差2.6;95%CI:2.1,3.1;p<0.001)。
- 年均手术频率从0.37±0.22降至0.07±0.15(均差0.30;95%CI:0.23,0.37;p<0.001)。
临床怎么用
- 对于接受ETI治疗的囊性纤维化患者,鼻窦手术需求可能显著降低,可据此优化耳鼻咽喉科随访与手术决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess whether elexacaftor-tezacaftor-ivacaftor (ETI) reduces the frequency of endoscopic sinus surgeries (ESS) in patients with cystic fibrosis (pwCF). METHODS: We conducted a retrospective chart review of pwCF aged 6 years and older who received ETI between January 1, 2018 and December 31, 2023. Inclusion criteria required a history of ESS and a follow-up time of at least 2 years before and after ETI initiation. Records were reviewed from up to 8 years prior to ETI through the most recent visit. The total number and frequency of ESS were evaluated using univariable linear models, estimating mean difference with 95% confidence intervals (CI) and p-values. RESULTS: Fifty-six patients met inclusion criteria, with a median follow-up time of 8 years (IQR: 8, 8) before ETI initiation and 4.13 years (IQR: 3.47, 4.78) after initiation of ETI. Median age at ETI initiation was 13 years (IQR: 10, 23). Among these patients, 98% (n = 55) required ESS prior to ETI, compared to 21% (n = 12) after ETI. The average number of sinus surgeries decreased from 2.88 ± 1.68 before ETI to 0.30 ± 0.63 after ETI (mean difference: 2.6; 95% CI: [2.1, 3.1]; p < 0.001). The frequency of surgeries per year dropped from 0.37 ± 0.22 to 0.07 ± 0.15 after beginning ETI (mean difference: 0.30; 95% CI: [0.23, 0.37]; p < 0.001). CONCLUSION: ETI was associated with a significant decrease in the frequency and rate of ESS in pwCF. These findings suggest an improvement in CF-related chronic rhinosinusitis outcomes following ETI and may influence future CF treatment decisions.
引用
- Lin A, Komara M, Kistler I, et al. Elexacaftor-Tezacaftor-Ivacaftor Reduces Revision Sinus Surgery in People With Cystic Fibrosis. Laryngoscope. 2025. PMID: 41342366. doi:10.1002/lary.70283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。